Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson's Disease
Interventions
Ropinirole Hydrochloride
Drug
Lead sponsor
Agarwal, Pinky, M.D.
Individual
Eligibility
25 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Englewood, Colorado
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
ropinirole CR-RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Jasper, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 41 more
Conditions
Bipolar Disorder
Interventions
ropinirole
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Cambridge, Massachusetts
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 55 more
Conditions
Parkinson Disease
Interventions
sumanirole, ropinirole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
93
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Carmichael, California + 81 more
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 25 more
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Depressive Disorder, Major
Interventions
Ropinirole CR
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Stanford, California
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson Disease
Interventions
Ropinirole XL (formerly CR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 7 more
Conditions
Parkinson Disease
Interventions
ropinirole/L-dopa, placebo/L-dopa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 6 more
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
59
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 54 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions

NCT00830219
Conditions
Healthy
Interventions
Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson Disease
Interventions
Ropinirole oral product, Ropinirole Implant
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington
Conditions
Muscle Cramp, Cirrhosis
Interventions
Vitamin E, Ropinirole, Muscle cramp survey
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Parkinson Disease
Interventions
ropinirole monotherapy, placebo monotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 8 more
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Conditions
Restless Legs Syndrome
Interventions
ropinirole dosing for up to 28 days
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ropinirole 0.25 mg Tablets Under Fasting Conditions

NCT00829504
Conditions
Healthy
Interventions
Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Sexual Dysfunction
Interventions
Ropinirole (Requip)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Immediate Release
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Macon, Georgia • Chicago, Illinois + 4 more